In a nutshell This study aimed to investigate the effectiveness of ibrutinib–rituximab treatment compared to standard chemoimmunotherapy in patients aged 70 or younger with previously untreated chronic lymphocytic leukemia (CLL). This study concluded that the ibrutinib–rituximab regimen provided...
Read MoreCurrent treatment status-Did not start treatment yet Posts on Medivizor
Can radioimmunotherapy help make chemotherapy more effective for patients with follicular lymphoma?
In a nutshell This study examined if Y-90 (Zevalin) improved the effectiveness of chemotherapy for follicular lymphoma. The authors found that Y-90 improved the effectiveness of chemotherapy and was generally safe. Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is usually treated with chemotherapy. BR...
Read MoreEvaluating outcomes for patients with follicular lymphoma after rituximab maintenance therapy
In a nutshell This study looked at long-term outcomes for patients with follicular lymphoma after rituximab (Rituxan) maintenance therapy. This study concluded that rituximab maintenance helped improve long-term survival without disease progression compared to no treatment. Some background Follicular lymphoma (FL) is the second most common type of...
Read MoreLooking for patients with prostate cancer to test a type of radiation treatment
In a nutshell This phase 3 trial will compare the safety and effectiveness of hypofractionated radiotherapy (HF-RT) to standard radiotherapy (RT). The main outcomes will be the number of grade 2 side effects and disease control. This trial is recruiting in Houston, Texas, United States. The details Radiation therapy (RT) is a...
Read MoreSearching for patients to try combinations of treatments for newly diagnosed multiple myeloma.
In a nutshell This study is looking for patients with newly diagnosed multiple myeloma (MM) to try different treatment regimens. The main outcome that will be measured is the number of patients who do not experience cancer worsening after treatment. This trial is recruiting in Chicago, Illinois, United States. The details There are several...
Read MoreCarfilzomib, melphalan and prednisone treatment for newly diagnosed elderly patients with multiple myeloma
In a nutshell This study aimed to investigate the maximum tolerated dose of carfilzomib plus melphalan and prednisone (KMP regimen) in patients with newly diagnosed elderly patients with multiple myeloma (MM). This study concluded that the maximum tolerated dose of carfilzomib was...
Read MoreEvaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...
Read MoreSearching for patients with untreated chronic lymphocytic leukemia to test combined immunotherapy
In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for chronic lymphocytic leukemia (CLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for CLL...
Read MoreVenetoclax – obinutuzumab combination treatment for patients with chronic lymphocytic leukemia and additional illness
In a nutshell This study aimed to investigate the effectiveness of the venetoclax (Venclexta) – obinutuzumab (Gazyva) combination in patients with chronic lymphocytic leukemia (CLL) and a coexisting condition. This study concluded that this combination provided better outcomes for these patients than a chlorambucil...
Read MoreNivolumab plus AVD chemotherapy for patients with advanced classical Hodgkin lymphoma
In a nutshell This study assessed the effectiveness of nivolumab (Opdivo) alone or with chemotherapy for patients with advanced classical Hodgkin lymphoma (cHL). This study concluded that nivolumab plus chemotherapy was promising, with manageable side effects for these patients. Some background Standard first-line chemotherapy is highly effective...
Read MoreEvaluating quality of life for survivors of melanoma after immunotherapy treatment
In a nutshell This study evaluated the quality of life for survivors of melanoma who received immunotherapy. This study found that melanoma survivors had a significantly lower quality of life compared to the general population. Some background Immune checkpoint inhibitors are a new class of anti-cancer drugs that take advantage of the...
Read MoreSearching for patients with prostate cancer to test low-dose or high-dose brachytherapy
In a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...
Read More
